Ospemifene versus local estrogen: adherence and costs in postmenopausal dyspareunia.

Ospemifene versus local estrogen: adherence and costs in postmenopausal dyspareunia. J Comp Eff Res. 2019 Aug 21;: Authors: Faught BM, Soulban G, Yeaw J, Maroun C, Coyle K, Schaffer S, DeKoven M Abstract Aim: Objective was to compare adherence and persistence, as well as direct healthcare costs and utilization, of ospemifene to available local estrogen therapies (LETs). Patients & methods: This retrospective database study used integrated medical and pharmacy claims data from the IQVIA Real-World Data Adjudicated Claims - US Database. Results: Ospemifene patients had significantly greater adherence and persistence compared with the other nonring LETs. Ospemifene had the lowest mean outpatient costs of any of the LET cohorts, including the estradiol vaginal ring. Total all-cause healthcare costs were also significantly less for ospemifene patients compared with all other LETs. PMID: 31432687 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research